Cargando…

The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials

Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. Although it is used for treating advanced non‐small‐cell lung cancer (NSCLC), its actual efficacy has not been determined. We searched PubMed, the Cochrane Library, Embase, MEDLI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Binghao, Zhang, Wenxiong, Yu, Dongliang, Xu, Jianjun, Wei, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943422/ https://www.ncbi.nlm.nih.gov/pubmed/29573217 http://dx.doi.org/10.1002/cam4.1387

Ejemplares similares

Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Xu, Zheng, et al.
Publicado: (2019)

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials
por: Liu, Qiangyun, et al.
Publicado: (2021)

Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
por: Zhao, Binghao, et al.
Publicado: (2017)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Neoadjuvant therapy of cetuximab combined with chemoradiotherapy in rectal cancer: A single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials
por: Yan, Qi, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
por: Song, Zhengbo, et al.
Publicado: (2016)

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
por: Martin-Broto, Javier, et al.
Publicado: (2020)

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
por: de la Torre-Aláez, Manuel, et al.
Publicado: (2022)

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

The Effect of Magnesium Intake on Stroke Incidence: A Systematic Review and Meta-Analysis With Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2019)

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Platform Trials — Beware the Noncomparable Control Group
por: Dodd, Lori E., et al.
Publicado: (2021)

Video-Assisted Thoracoscopic Sympathectomy for Palmar Hyperhidrosis: A Meta-Analysis of Randomized Controlled Trials
por: Zhang, Wenxiong, et al.
Publicado: (2016)

Thoracotomy is better than thoracoscopic lobectomy in the lymph node dissection of lung cancer: a systematic review and meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2016)

Stereotactic Biopsy for Brainstem Lesions: A Meta-analysis with Noncomparative Binary Data
por: He, Lin, et al.
Publicado: (2021)

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
por: Hall, Evan, et al.
Publicado: (2020)

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
por: Altan, Mehmet, et al.
Publicado: (2023)

Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non–small cell lung cancer
por: Zeng, Weibiao, et al.
Publicado: (2020)

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies
por: He, Liyun, et al.
Publicado: (2019)

Gastric-tube versus whole-stomach esophagectomy for esophageal cancer: A systematic review and meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2017)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

A systematic review and meta-analysis of T2, T3 or T4, to evaluate the best denervation level for palmar hyperhidrosis
por: Zhang, Wenxiong, et al.
Publicado: (2017)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Effects of Vessel Interruption Sequence During Lobectomy for Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Long, Xiang, et al.
Publicado: (2021)

The Memory Metal Minimal Access Cage: A New Concept in Lumbar Interbody Fusion—A Prospective, Noncomparative Study to Evaluate the Safety and Performance
por: Kok, D., et al.
Publicado: (2012)

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
por: Ono, Kana, et al.
Publicado: (2021)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
por: Recchia, Francesco, et al.
Publicado: (2012)

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
por: Ardizzoni, Andrea, et al.
Publicado: (2021)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer
por: Sun, Lin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4gm2pqrimg6bep486clrv7pvr